8-K: NovaBay Pharmaceuticals Faces Delisting Threat Despite Reverse Stock Split Approval

NovaBay Pharmaceuticals received a second notice from the NYSE American for failing to meet minimum stockholders' equity requirements, despite shareholder approval of a 1-for-35 reverse stock split.

Summary

• NovaBay Pharmaceuticals received a notice from the NYSE American stating they are not in compliance with minimum stockholders' equity requirements.
• The company's stockholders' equity was reported as $160 thousand as of March 31, 2024, which is below the required $2.0 million.
• This is the second deficiency notice received, with the first notice citing non-compliance with higher equity requirements.
• The company has until October 18, 2025, to regain compliance or face potential delisting.
• Shareholders approved a 1-for-35 reverse stock split at the annual meeting.
• The reverse stock split is intended to increase the per-share price and help the company meet listing requirements.
• The reverse stock split will be effective on May 30, 2024, and trading on a split-adjusted basis will begin on May 31, 2024.
• The number of outstanding shares will decrease from approximately 40.3 million to 1.15 million due to the reverse stock split.
• All proposals at the 2024 Annual Meeting were approved by stockholders, including the reverse stock split and the issuance of new shares related to warrants and convertible notes.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the second delisting notice, low stockholders' equity, and the going concern issue, despite the approval of the reverse stock split. The company is in a precarious financial position.

Positives

• All proposals at the 2024 Annual Meeting were approved by stockholders, including the reverse stock split.
• The reverse stock split is expected to increase the per-share price, potentially improving marketability and liquidity.
• The company has a plan to regain compliance with NYSE American listing standards.

Negatives

• NovaBay received a second notice of non-compliance with NYSE American listing standards regarding minimum stockholders' equity.
• The company's current stockholders' equity is significantly below the required $2.0 million.
• The company faces potential delisting if it does not regain compliance by October 18, 2025.
• The company's audited financial statements included an explanatory paragraph related to the company's ability to continue as a going concern.

Risks

• The company faces the risk of delisting from the NYSE American if it does not meet the minimum stockholders' equity requirements by October 18, 2025.
• The reverse stock split may not be sufficient to regain compliance with listing standards.
• The company's ability to continue as a going concern is in question, as noted in the audit opinion.
• The company's stock price may be volatile due to the reverse stock split and delisting concerns.

Future Outlook

The company aims to regain compliance with NYSE American listing standards through the reverse stock split and other strategic initiatives, but faces potential delisting if it fails to do so by October 18, 2025.

Management Comments

• We thank stockholders for their support in approving all proposals during our annual meeting, said Justin Hall, NovaBays CEO.
• The approval of these proposals allows us to move forward with several strategic initiatives meant to help us regain compliance with NYSE Americans continued listing standards and grow our business.
• We believe the anticipated increased market price resulting from the reverse split will improve the marketability and liquidity of our stock and could encourage additional interest and trading.

Industry Context

The company's struggles to maintain listing compliance highlight the challenges faced by smaller pharmaceutical companies in achieving profitability and maintaining sufficient equity. The reverse stock split is a common tactic used by companies facing delisting, but it does not guarantee long-term success.

Comparison to Industry Standards

• Many small-cap pharmaceutical companies face challenges in maintaining listing compliance, particularly those with ongoing losses.
• A reverse stock split is a common strategy for companies facing delisting, but its effectiveness varies.
• Companies like Agenus Inc. and Cassava Sciences have also faced challenges with stock price and listing compliance, highlighting the volatility in the biotech sector.
• The minimum stockholders' equity requirement of $2.0 million is a standard benchmark for continued listing on exchanges like NYSE American.

Stakeholder Impact

• Shareholders face the risk of further stock dilution and potential delisting.
• Employees may be concerned about the company's financial stability.
• Customers and suppliers may be impacted by the company's financial challenges.

Next Steps

• The company will implement the 1-for-35 reverse stock split on May 30, 2024.
• The company will continue to work on its plan to regain compliance with NYSE American listing standards.
• The company will need to demonstrate substantial progress towards meeting the minimum stockholders' equity requirements by October 18, 2025.

Key Dates

Keywords

reverse stock split, NYSE American, delisting, stockholders equity, compliance, annual meeting, NBY, going concern